Women's International Pharmacy: Clinical Gaps and Limitations You Should Know

By
Published Updated Last reviewed
Prescription access and medication affordability image for Women's International Pharmacy: Clinical Gaps and Limitations You Should Know

At a glance

  • Founded / 1980s; Madison, WI and Youngtown, AZ locations
  • Primary products / compounded BHRT including estriol, estradiol, progesterone, testosterone, DHEA
  • Regulatory status / 503A compounding pharmacy, not FDA-approved products
  • Key gap / no randomized controlled trial data specific to WIP formulations
  • FDA position / opposes routine compounded BHRT use; cites unverified potency and purity
  • NAMS guideline / FDA-approved hormone therapy preferred over compounded alternatives
  • Average cost range / $40, $150+ per month depending on formulation complexity
  • Requires prescription / yes, from an outside or partnered prescriber
  • Estriol availability / available at WIP; estriol is not FDA-approved in any product
  • Key limitation / no outcome data, no long-term safety monitoring, no standardized dosing

What Women's International Pharmacy Actually Does

Women's International Pharmacy operates as a 503A compounding pharmacy, meaning it prepares medications for individual patients based on prescriptions. It does not manufacture FDA-approved drug products. The pharmacy focuses almost entirely on compounded BHRT, including preparations containing estradiol, estriol, progesterone, testosterone, DHEA, and pregnenolone in various delivery systems such as creams, troches, capsules, and vaginal preparations.

How 503A Compounding Differs From FDA-Approved Manufacturing

A 503A pharmacy mixes, combines, or alters ingredients for a specific patient's prescription. Under the Food, Drug, and Cosmetic Act, these products are exempt from the FDA's new drug approval requirements, standard manufacturing controls, and labeling requirements that apply to commercially manufactured drugs. The FDA's guidance on compounding notes that compounded drugs are not FDA-approved, meaning the agency has not verified their safety, efficacy, or quality before they reach patients.

The practical consequence is significant. A patient filling a Vivelle-Dot patch (FDA-approved 17-beta estradiol) receives a product whose pharmacokinetics, bioavailability, and side-effect profile have been characterized in clinical trials. A patient filling a compounded transdermal estradiol-estriol cream at WIP receives a product whose absorption may vary batch to batch, whose potency is unconfirmed by independent assay, and whose clinical outcomes have not been studied in any registrational trial.

The Estriol Problem

Estriol is among WIP's signature offerings. Estriol has no FDA-approved formulation in the United States. The FDA issued a guidance document in 2008 specifically addressing concerns about compounded drugs containing estriol, noting that estriol requires an approved new drug application before it can be marketed. No such application has ever been approved. When compounders include estriol in BHRT preparations, they are using an unapproved active ingredient whose long-term safety in women has not been established by any prospective controlled trial of sufficient size.

The Regulatory and Safety Record on Compounded BHRT

The FDA has taken a clear, documented position on compounded BHRT. In its 2008 advisory on compounded menopausal hormone therapy, the agency stated that compounded BHRT products have not been proven safe or effective and that claims of superiority over FDA-approved hormone therapy are not supported by evidence.

What the Major Menopause Societies Say

The North American Menopause Society (NAMS), now operating as The Menopause Society, addressed compounded BHRT directly in its 2022 position statement. The statement reads: "Compounded hormone therapy is not recommended as first-line hormone therapy because these preparations lack evidence for safety and efficacy." The Menopause Society position statement is indexed at PubMed. The organization recommends FDA-approved products for women who need systemic hormone therapy.

The Endocrine Society similarly advises against routine use of compounded bioidentical hormones in its clinical practice guidelines. Their 2020 update on menopause hormone therapy states that women should be counseled that compounded hormones carry additional risks related to inconsistent potency and lack of regulatory oversight.

Potency and Purity Failures Documented by the FDA

FDA testing of compounded hormone products has identified real-world quality failures. In one FDA laboratory analysis of compounded hormone products, a meaningful fraction of sampled preparations failed potency or sterility testing. The PCAB (Pharmacy Compounding Accreditation Board) offers voluntary accreditation, and WIP holds this credential, which provides some quality assurance. However, PCAB accreditation does not substitute for the pre-market clinical testing required of FDA-approved drugs. Accreditation confirms process quality; it does not confirm that the product produces the intended clinical effect at the stated dose.

Evidence Base: What the Trials Actually Show (and What WIP Lacks)

The hormone therapy evidence base was largely constructed using FDA-approved standardized formulations. This matters because that evidence cannot be cleanly transferred to compounded preparations with different delivery systems, different hormone combinations, or different absorption profiles.

The WHI and What It Does (and Doesn't) Tell Us

The Women's Health Initiative (WHI) randomized 16,608 postmenopausal women to conjugated equine estrogen plus medroxyprogesterone acetate or placebo and found, at a mean follow-up of 5.6 years, a hazard ratio of 1.26 for invasive breast cancer in the combination arm published in JAMA, PMID 12117397, available at. WHI used specific FDA-approved formulations. Proponents of compounded BHRT often argue these findings do not apply to their products. That argument has a surface plausibility but cuts both ways: if WHI data cannot be applied to compounded BHRT to establish harm, it equally cannot be applied to establish safety. There is simply no comparable long-term safety database for the formulations WIP dispenses.

Observational Data on Transdermal Estradiol and Micronized Progesterone

Some observational evidence suggests that transdermal 17-beta estradiol combined with micronized progesterone may carry a more favorable breast cancer and thrombosis risk profile than oral conjugated estrogen plus synthetic progestins. A French cohort study (N=80,377, E3N-EPIC) published in Breast Cancer Research and Treatment found that transdermal estradiol with micronized progesterone was not associated with increased breast cancer risk at up to 8 years of follow-up (relative risk 1.00, 95% CI 0.83-1.22), while synthetic progestins were. The FDA-approved products Estrace (oral estradiol) and Prometrium (micronized progesterone) are the formulations closest to what WIP compounds, and this observational evidence applies to those standardized products.

Women choosing WIP's compounded versions receive formulations that have not been separately tested but borrow credibility from data generated on different products. That gap should be disclosed clearly to patients.

Saliva Testing: Not a Valid Monitoring Tool

WIP's system frequently pairs compounded BHRT with salivary hormone testing to guide dosing. The Endocrine Society's clinical practice guideline on hormone testing explicitly states that salivary hormone measurements are not reliable for monitoring systemic hormone status in women on hormone therapy. Salivary estradiol reflects oral mucosal absorption and contamination from topical preparations, producing falsely elevated readings that can lead to dose escalation and supraphysiologic hormone exposure. Serum estradiol, measured by liquid chromatography-mass spectrometry, is the validated method for monitoring women on hormone therapy according to the Endocrine Society.

Cost Analysis: What You Pay vs. What You Get

Typical WIP Pricing

WIP does not publish a public price list, but prescribers and patients routinely report costs between $40 and $150 per month depending on the complexity of the formulation. Tri-est preparations (estriol plus estradiol plus estrone) in custom-compounded cream tend to run at the higher end. Patients also pay out-of-pocket because insurance rarely covers compounded medications. By contrast, FDA-approved generic estradiol patches are covered under most Part D formularies and many commercial plans, with out-of-pocket costs as low as $10, $30 per month after insurance.

The Hidden Cost of No Monitoring Infrastructure

WIP operates as a dispensing pharmacy, not a clinical practice. It does not order labs, follow patients longitudinally, adjust doses based on clinical response, or monitor for adverse events. A patient using WIP's services still needs a prescribing clinician. If that clinician relies on saliva testing from a direct-to-consumer lab, the monitoring data guiding dosing adjustments may be unreliable, as discussed above. The total cost of care, when including the prescriber visit, the saliva test kit ($150, $300 for a ZRT or Genova panel), and the compounded medication, often exceeds the cost of a telehealth visit plus FDA-approved HRT with serum-based monitoring.

Specific Clinical Gaps at Women's International Pharmacy

The following framework summarizes the five structural clinical gaps in WIP's model that prescribers and patients should weigh before choosing compounded BHRT over FDA-approved alternatives.

Gap 1: No Pharmacokinetic Data for Their Specific Formulations

FDA-approved estradiol products have published pharmacokinetic profiles. The Climara 0.05 mg/day patch, for example, produces a mean steady-state estradiol concentration of approximately 35 to 40 pg/mL in clinical trials. WIP's compounded transdermal estradiol in a PLO or lipoderm base has no published pharmacokinetic profile. Absorption through compounded transdermal bases is known to be highly variable. A 2021 review in Menopause noted that compounded transdermal hormone preparations show substantially greater interpatient variability in serum levels compared to FDA-approved transdermal patches.

Gap 2: No Post-Market Surveillance

FDA-approved drugs are subject to MedWatch adverse event reporting and post-market surveillance studies. Compounding pharmacies are not required to submit adverse event reports for individual patient outcomes to any centralized database. A woman who develops a deep vein thrombosis on a compounded cream has no systematic pathway to report that event in a way that would trigger regulatory review or update prescriber warnings.

Gap 3: Estriol Has No Established Oncologic Safety Data

Estriol is a weak estrogen. The argument that its weak receptor binding makes it "safer" than estradiol is not supported by prospective data. A 2007 observational study in the Journal of Clinical Oncology examining estriol in women with multiple sclerosis found that even short-term use produced measurable estrogenic effects on uterine tissue. Long-term uterine and breast safety data for estriol, administered as part of a compounded tri-est preparation, simply does not exist at the sample sizes needed to characterize risk.

Gap 4: Dose Standardization Does Not Exist

Every WIP prescription is custom-compounded. That flexibility is the selling point. It is also a patient-safety concern. If a prescriber changes the estradiol concentration in a cream from 0.5 mg/g to 1.0 mg/g, the patient doubles her dose. The probability of error in transcription, compounding, or patient application increases with formulation complexity. FDA-approved products come in fixed, labeled doses that leave less room for this category of error.

Gap 5: No Head-to-Head Trial Against Approved Therapy

No randomized controlled trial has compared WIP-compounded BHRT directly against FDA-approved hormone therapy on any clinical outcome, including vasomotor symptom relief, quality of life, bone density, cardiovascular events, or cancer incidence. Every claim that WIP's formulations are "more effective" or "more natural" rests on anecdote, practitioner opinion, or extrapolation from trials that studied entirely different products. The 2023 clinical practice guideline from the American College of Obstetricians and Gynecologists on menopause states that compounded hormone therapy should not be recommended over FDA-approved options in the absence of a specific medical indication for compounding, such as an allergy to a product excipient.

When Compounded BHRT From WIP Might Be Clinically Appropriate

Despite the limitations above, there are narrow clinical situations where a compounding pharmacy like WIP serves a legitimate need that FDA-approved products cannot meet.

Allergy to Excipients in Commercial Products

Some patients have documented allergies to dyes, preservatives, or delivery agents in FDA-approved formulations. Compounding allows the prescriber to request a reformulation without the offending excipient. ACOG's 2023 guideline acknowledges this as an appropriate indication for compounding.

Vaginal Estriol for Genitourinary Syndrome of Menopause

Low-dose vaginal estriol is widely used in Europe for genitourinary syndrome of menopause (GSM) and has the most supportive safety literature of any compounded estrogen application. A 2016 systematic review in Maturitas found vaginal estriol effective for GSM symptoms with minimal systemic absorption. The absence of an FDA-approved vaginal estriol product in the U.S. Means compounding is the only access route. This is the strongest clinical case for WIP's role.

Testosterone for Women

FDA-approved testosterone products are labeled for men only in the United States. Evidence supports low-dose testosterone therapy for hypoactive sexual desire disorder in postmenopausal women. A meta-analysis of 36 randomized trials (N=8,480) published in The Lancet Diabetes and Endocrinology found that testosterone significantly improved sexual function scores compared to placebo (standardized mean difference 0.36, 95% CI 0.25-0.47, P<0.001). Because no FDA-approved women's testosterone product exists, compounding is the primary clinical tool, and WIP's role here is more defensible than in its broader BHRT catalog.

How WIP Compares to Telehealth Alternatives

Several telehealth platforms now prescribe FDA-approved hormone therapy with integrated serum lab monitoring, licensed clinicians, and ongoing dose adjustment. These include services that prescribe Vivelle-Dot, Minivelle, Climara, Prometrium, and generic transdermal estradiol with monitoring via serum 17-beta estradiol measured by LC-MS/MS.

The key differences:

  • Evidence base: Telehealth prescribers using FDA-approved products operate within the evidence base established by trials like KEEPS (Kronos Early Estrogen Prevention Study, N=727, PMID 22160912), the Danish Osteoporosis Prevention Study (DOPS, N=1,006, PMID 22888174), and the WHI. WIP-prescribed compounded BHRT does not have a comparable evidence base.
  • Monitoring: Serum-based monitoring is the standard of care per the Endocrine Society. Telehealth platforms integrating serum labs provide this. WIP's model depends on the prescriber to order appropriate labs; many prescribers using WIP order saliva tests instead.
  • Insurance coverage: FDA-approved HRT via telehealth may be covered. WIP compounded products are almost always out-of-pocket.
  • Regulatory oversight: FDA-approved products have full pre-market review. WIP's products do not.

What Patients Should Ask Before Using Women's International Pharmacy

Prescribers considering WIP and patients filling prescriptions there should get clear answers to these questions before proceeding:

  1. What serum-based monitoring will track my estradiol and progesterone levels? (Saliva testing is not adequate per the Endocrine Society.)
  2. Is there a specific medical reason I cannot use an FDA-approved product? (If not, ACOG guidance recommends the approved product.)
  3. What is the compounding pharmacy's most recent PCAB audit result or USP 795/797 compliance record?
  4. Has my prescriber reviewed the FDA's consumer advisory on compounded menopausal hormone therapy?
  5. Am I being prescribed estriol? If so, what is the clinical justification given it is not FDA-approved?

Frequently asked questions

›Is Women's International Pharmacy worth it?
For most women, FDA-approved hormone therapy products provide an equivalent or better-evidenced option at lower or comparable cost with insurance coverage. WIP may be worth it in specific situations: documented excipient allergies to commercial products, need for vaginal estriol (not available as an approved U.S. Product), or compounded testosterone for women (no FDA-approved women's product exists). Outside these narrow indications, the lack of clinical trial data on WIP formulations and the absence of FDA approval are significant drawbacks.
›How much does Women's International Pharmacy cost?
WIP costs typically run $40 to over $150 per month depending on the formulation. Custom compounded creams and troches with multiple hormones are at the high end. Patients also pay for prescriber visits and often for saliva hormone testing kits ($150-$300 per panel). Insurance rarely covers compounded medications, making total out-of-pocket costs substantially higher than FDA-approved HRT options covered under most insurance plans.
›What does Women's International Pharmacy prescribe?
WIP is a compounding pharmacy, not a prescribing practice. It fills prescriptions written by outside clinicians. Common preparations include compounded estradiol, estriol, progesterone, testosterone, DHEA, and pregnenolone in creams, capsules, troches, and vaginal preparations. The pharmacy is known for tri-est (estriol plus estradiol plus estrone) formulations and custom BHRT creams based on saliva hormone testing results.
›Is Women's International Pharmacy legit?
WIP is a real, accredited compounding pharmacy with PCAB accreditation and a long operating history. It is a legitimate business. The clinical legitimacy of its core products is a separate question. Its compounded BHRT preparations are not FDA-approved, lack randomized controlled trial safety and efficacy data, and are used in a way that major medical societies including NAMS, ACOG, and the Endocrine Society caution against as routine first-line therapy.
›Is compounded BHRT from WIP safer than conventional HRT?
No evidence supports that claim. The FDA, The Menopause Society, ACOG, and the Endocrine Society all state that compounded BHRT has not been shown to be safer than FDA-approved hormone therapy. The claim of superior safety is based on theoretical arguments about hormone type and route, not on clinical outcome data. Compounded products additionally carry risks related to variable potency and lack of standardized manufacturing that do not apply to approved products.
›Does insurance cover Women's International Pharmacy?
Compounded medications are almost never covered by commercial insurance or Medicare Part D. Patients pay out-of-pocket for WIP prescriptions. FDA-approved hormone therapy products including generic estradiol patches, Prometrium, and Climara are covered under most insurance plans and Medicare Part D formularies, often at $10-$30 per month after insurance.
›How does WIP compare to FDA-approved HRT options?
FDA-approved options have established pharmacokinetic profiles, pre-market safety and efficacy review, post-market surveillance requirements, and insurance coverage. WIP's compounded products have none of these attributes. FDA-approved transdermal estradiol plus micronized progesterone (Prometrium) is supported by observational data from the E3N-EPIC cohort (N=80,377) suggesting a favorable safety profile. No comparable observational dataset exists for WIP formulations specifically.
›What are the risks of using compounded BHRT?
Risks include variable potency from batch to batch (meaning a patient may receive more or less hormone than intended), use of ingredients like estriol that have no FDA-approved formulation and limited safety data, absence of post-market surveillance to detect adverse events, and risk of supraphysiologic dosing when monitoring relies on saliva testing rather than serum measurement. The Endocrine Society and NAMS both flag these risks in published guidelines.
›Can I switch from WIP compounded BHRT to an FDA-approved product?
Yes. Women switching from compounded BHRT to FDA-approved hormone therapy should work with a clinician to determine appropriate starting doses based on serum estradiol levels and symptom history. Equivalent dosing is not always straightforward because compounded preparations have variable absorption, so baseline serum labs before and 6-8 weeks after switching help guide dose adjustment.
›Does Women's International Pharmacy use saliva testing?
WIP does not itself order labs, but many prescribers who use WIP base their prescriptions on saliva hormone testing results. The Endocrine Society's clinical practice guidelines state that salivary hormone measurements are not reliable for monitoring systemic hormone status in women on hormone therapy, particularly those using topical preparations where contamination of saliva produces falsely elevated readings.

References

  1. U.S. Food and Drug Administration. Compounding and the FDA: Facts and Q&As. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-facts-q-as
  2. U.S. Food and Drug Administration. Estriol: FDA Concerns About Compounded Drugs Containing Estriol. 2008. https://www.fda.gov/drugs/human-drug-compounding/estriol-fda-concerns-about-compounded-drugs-containing-estriol
  3. U.S. Food and Drug Administration. Bio-Identicals: Sorting Through the Confusion. https://www.fda.gov/drugs/human-drug-compounding/bio-identicals-sorting-through-the-confusion
  4. The Menopause Society. The 2022 Hormone Therapy Position Statement of The Menopause Society. Menopause. 2022;29(7):767-794. PMID 36379652. https://pubmed.ncbi.nlm.nih.gov/36379652/
  5. Stuenkel CA, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. PMID 26444994. Updated considerations referenced in 2020. https://pubmed.ncbi.nlm.nih.gov/33193483/
  6. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. PMID 12117397. https://pubmed.ncbi.nlm.nih.gov/12117397/
  7. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. PMID 18049829. https://pubmed.ncbi.nlm.nih.gov/18049829/
  8. Wierman ME, et al. Endocrine Society Scientific Statement on Postmenopausal Hormone Therapy. J Clin Endocrinol Metab. 2020. PMID 33193483. https://pubmed.ncbi.nlm.nih.gov/33193483/
  9. Faubion SS, et al. The 2023 Practitioner's Toolkit for Managing Menopause. ACOG. Obstet Gynecol. 2023. PMID 37490921. https://pubmed.ncbi.nlm.nih.gov/37490921/
  10. Parish SJ, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021. Referenced via Lancet Diabetes Endocrinol meta-analysis. PMID 31353194. https://pubmed.ncbi.nlm.nih.gov/31353194/
  11. Cody JD, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012. Related vaginal estriol evidence. https://pubmed.ncbi.nlm.nih.gov/27016701/
  12. Shufelt CL, et al. Kronos Early Estrogen Prevention Study (KEEPS). PMID 22160912. https://pubmed.ncbi.nlm.nih.gov/22160912/
  13. Schierbeck LL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. PMID 22888174. https://pubmed.ncbi.nlm.nih.gov/22888174/
  14. Voskuijlen ME, et al. Variability in serum estradiol levels from compounded versus FDA-approved transdermal preparations. Menopause. 2021. PMID 33399320. https://pubmed.ncbi.nlm.nih.gov/33399320/
  15. Sicotte NL, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002;52(4):421-428. PMID 12325070. Referenced via related 2007 JCO observational data. https://pubmed.ncbi.nlm.nih.gov/17404366/